[{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Armata Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"AP-PA02","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Armata Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"AP-PA02","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"SpliSense","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Calithera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CB-280","moa":"||Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Kinnear Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"CSA-131","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Polyphor","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Murepavadin","moa":"||Imp protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Nitric Oxide","moa":"||sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fibrosis Foundation \/ Synspira Therapeutics"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cystic Fibrosis Foundation \/ Royalty Pharma"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Pulmocide","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Opelconazole","moa":"||CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"BX004","moa":"||P. aeruginosa biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"||Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"4D-710","moa":"||CFTR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Microbion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Pravibismane","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"ContraFect Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Exebacase","moa":"||26-kDa","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Peptilogics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Nanite","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Crestone","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Inapplicable","moa":"||MmpL3","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Gensaic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"}]
Find Clinical Drug Pipeline Developments & Deals by Cystic Fibrosis Foundation
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
